Findings

What do systematic reviews say?

23 questions · 23 findings · 3 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 4.3%GRADE not reported 3 · 13%Very low 0 · 0%Low 4 · 17.4%Moderate 3 · 13%High 12 · 52.2%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Oral creatine vs placebo · Change in total muscle strength (total muscle strength)
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low
Direct match · question page
- Oral creatine vs placebo · Time from beginning of treatment until death or full‐time ventilation
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Moderate
Direct match · question page
- Oral creatine vs placebo · Change in disability score
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Moderate
Direct match · question page
- Oral creatine vs placebo · Acquiring the ability to stand or walk
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Oral creatine vs placebo · Change in pulmonary function
  Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low

Oral creatine vs placebo

Change in disability score · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Oral creatine vs placebo

Muscle strength · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Oral creatine vs placebo

Acquiring the ability to stand or walk · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral creatine vs placebo

Change in pulmonary function · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Oral creatine vs placebo

Time from beginning of treatment until death or full‐time ventilation · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Oral creatine vs placebo

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Intervention not reported

Maximum voluntary contraction in dystrophinopathies % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 121 participants
High

Intervention not reported

Adverse events in glycogen storage disease type V · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 28 participants
GRADE not reported

Intervention not reported

Aggregate functional performance time (AFPT), intention‐to‐treat analysis % · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
High

Intervention not reported

AFPT, valid compliant completer analysis % · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
High

Intervention not reported

Adverse events · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

Intervention not reported

Maximum voluntary contraction in myotonic dystrophy type 1 % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Intervention not reported

Maximum voluntary contraction in myotonic dystrophy type 2 % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
High

Intervention not reported

Adverse events · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 261 participants
High

Intervention not reported

Global assessment of improvement felt better · patients with muscular dystrophies

The intervention leads to higher global assessment of improvement felt better (high certainty).

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
RR 4.51 [2.33, 8.74]
4 studies · 183 participants
High

Intervention not reported

Maximum voluntary contraction in mitochondrial diseases % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
High

Intervention not reported

Maximum voluntary contraction in glycogen storage disease type V % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
High

Intervention not reported

Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
High

Intervention not reported

Adverse events in mitochondrial diseases · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 38 participants
GRADE not reported